Comprehensive Genomic Profiling (CGP) in the U.S. - Medical Oncologist, Specialty Pacific Medium IHN

In a recent discussion with a medical oncologist regarding the role of CGP testing in their clinic, they shared that it is essential for treatment decision-making and prognostication. The stakeholder values panel depth and additional add-ons such as RNA and HRD to ensure coverage of all actionable markers. When it comes to choosing a CGP vendor, they mention the importance of turnaround time and insurance authorization. Companies they view most favorably excel in providing fast results and efficiently handling insurance approvals. In addition, EMR integration is seen as important for streamlining the ordering process. They also believe that ancillary genomic testing offerings like MRD and ctDNA will become more important in the future.

‍